Characterization of homologous restriction factor (HRF20) in human skin and leucocytes

Complement regulatory proteins in normal human esophagus and esophageal squamous cell carcinoma

BACKGROUND

Altered expression of three complement regulatory proteins, decay-accelerating factor (CD55), membrane cofactor protein (CD46) and homologous restriction factor 20 (CD59) has been identified in human gastrointestinal malignancies, but their expression in esophageal cancer has not been described. Therefore the purpose of the present paper was to study the distribution of these proteins in human normal and malignant esophageal mucosa.

METHODS AND RESULTS

In the normal esophageal mucosa, CD55 predominantly stained on the cell membrane of squamous epithelium in the superficial and prickle cell layers, whereas CD46 most intensely stained on the cell membrane in the basal and parabasal cell layers. In contrast to this reciprocal expression of CD55 and CD46, CD59 was broadly distributed on the cell membrane in all layers. In the esophageal squamous cell carcinoma, CD55 staining was intense in the stroma but was negligible in the cancer cells. In contrast, CD46 and CD59 stained almost uniformly on the tumor cell membrane. There was a significant difference in the intensity of the staining of CD55 and CD46 among cells in various layers of normal esophageal mucosa and esophageal carcinoma cells, but not in the staining of CD59. Similar expression patterns of the three complement regulatory proteins in carcinoma cells and in normal epithelium in the basal and parabasal cell layers were observed.

CONCLUSIONS

These observations on the expression of the three complement regulatory proteins would help understanding of the host immune responses involving the complement system against esophageal squamous cell carcinoma.

Complement regulatory proteins and selective vulnerability of neurons to lysis on exposure to acetylcholinesterase antibody

Systemic injection of antibodies against acetylcholinesterase (AChE) induces complement-mediated destruction of preganglionic nerve terminals in paravertebral sympathetic ganglia, but spares other AChE-rich structures, such as nerve terminals in prevertebral sympathetic ganglia, parasympathetic ganglia, and the neuromuscular junction. This pattern of differing sensitivity to "AChE immunolesion" might be explained by a differing expression of proteins that serve to protect host cells from complement activation. Two major complement regulatory proteins in rats are Crry, which interferes with the assembly of C3 convertase, and CD59, which blocks formation of the terminal cytolytic membrane attack complex. The present study used immunohistochemistry to demonstrate an inverse relation between levels of CD59 and Crry expression and sensitivity to AChE immunolesion in several AChE-rich targets. Thus, the most sensitive structures, i.e., preganglionic nerve terminals in the adrenal gland and superior cervical ganglion (SCG), expressed undetectable levels of CD59 and Crry immunoreactivities. By contrast, AChE-rich, but antibody-resistant, cholinergic nerve terminals in the inferior mesenteric ganglia (IMG) and diaphragm muscle expressed significant amounts of CD59 and Crry. Such expression was functionally important because, after membrane-anchored CD59 was removed from explanted IMG with phosphatidylinositol phospholipase C, exposure to AChE antibody and complement caused greater immunolesion. It was concluded that differential expression of regulatory proteins in different parts of the nervous system influences regional vulnerability to complement mediated damage.

Phenotypic changes that TCR V gamma 3+ fetal thymocytes undergo during their maturation into dendritic epidermal T cells

Murine Thy-1+, TCR V gamma 3/V delta 1+ dendritic epidermal T cells (DETC) express CD2 antigens, but differ from most other T-cell subsets in their absence of CD4, CD5, and CD8 antigens. To determine whether negativity for those antigens is an intrinsic feature of a given T-cell population or whether such triple-negative T cells go through a maturational stage during which they express these antigens, we determined the phenotype of TCR V gamma 3+ fetal thymocytes, which are the precursor cells of DETC. We found that TCR V gamma 3+ fetal thymocytes at day 17 of gestation are CD2+, CD5+, mostly CD8+, and partly CD4+. The expression of CD5 is highest on early TCR V gamma 3+ thymocytes; these cells express intermediate levels of CD5 when they leave the thymus and lose CD5 expression until or shortly after arrival in the epidermis. A similar loss of CD5 expression by TCR V gamma 3+ cells was observed in vitro under various culture conditions. To determine whether expression of CD5 is important for the maturation of DETC, we searched for these cells in the epidermis of CD5-deficient mice. There was no alteration in the number of Thy-1+/TCR V gamma 3+ dendritic cells in the epidermis of CD5-/- mice. Even though the latter finding speaks against a pivotal role of CD5 during the maturation of DETC, the described cell system may serve as a useful tool in further experiments aimed to clarify the function of the CD5 glycoprotein as well as the mechanism(s) regulating its expression.

CD5- dendritic epidermal T cells are derived from CD5+ precursor cells

Murine Thy-1+, TcR V gamma 3/V delta 1+ dendritic epidermal T cells (DETC) differ from most other T cell subsets by the absence of CD4 and CD8 antigens as well as the lack of CD5 expression. To see whether negativity for those antigens is an intrinsic feature of a given T cell population or if such triple-negative T cells go through a maturational stage where they express these antigens, we determined the phenotype of TcR V gamma 3+ fetal thymocytes which are the precursor cells of DETC. We found that TcR V gamma 3+ fetal thymocytes phenotypically differ from mature DETC in that they are CD5+, mostly CD8+ and partly CD4+. The injection of fetal thymic suspensions containing TcR V gamma 3+/CD5+ (but not TCR V gamma 3+/CD5-) thymocytes into Thy-1-disparate athymic nude mice resulted in the appearance of donor-type TcR V gamma 3+/CD5- dendritic cells in the recipients' epidermis, indicating that TcR V gamma 3+ thymocytes are indeed the precursors of CD5- DETC. Tracing CD5 expression on DETC precursors during their intrathymic maturation and their migration to the fetal skin, we found that (i) the earliest DETC precursor cells as defined by TcR V gamma 3 expression express high levels of CD5 antigen (day 15 of gestation), (ii) after day 16 of gestation 70% of TcR V gamma 3+ thymocytes express high and 30% express intermediate levels of CD5, (iii) TcR V gamma 3+ cells in the fetal blood express low levels of CD5, (iv) the first TcR V gamma 3+ cells entering the epidermis express very low levels of this antigen and (v) TcR V gamma 3+ epidermal cells later than day 19 of gestation are CD5-. A similar down-regulation of CD5 expression on DETC precursors was also noted when TcR V gamma 3+ cells were cultured in vitro. Even the addition of PMA and ionomycin, which up-regulates CD5 expression on TcR alpha/beta-bearing thymocytes and lymph node T cells, could not prevent CD5 down-regulation on DETC precursors. The described cell system may serve as a useful tool in further experiments aimed to clarify the function of the CD5 glycoprotein as well as the mechanism(s) regulating its expression.

Membrane defence against complement lysis: the structure and biological properties of CD59

The complement system is an important branch of the innate immune response, constituting a first line of defence against invading microorganisms which activate complement via both antibody-dependent and -independent mechanisms. Activation of complement leads to (a) a direct attack upon the activating cell surface by assembly of the pore-forming membrane attack complex (MAC), and (b) the generation of inflammatory mediators which target and recruit other branches of the immune system. However, uncontrolled complement activation can lead to widespread tissue damage in the host, since certain of the activation products, notably the fragment C3b and the C5b-7 complex, can bind nonspecifically to any nearby cell membranes. Therefore it is important that complement activation is tightly regulated. Our own cells express a number of membrane-bound control proteins which limit complement activation at the cell surface and prevent accidental complement-mediated damage. These include decay-accelerating factor, complement receptor 1 and membrane cofactor protein, all of which are active at the level of C3/C5 convertase formation. Until recently, cell surface control of MAC assembly had been attributed to a single 65-kD membrane protein called homologous restriction factor (alternatively named C8-binding protein and MAC-inhibiting protein). However a second MAC-inhibiting protein has since been discovered and it is now clear that this protein plays a major role in the control of membrane attack. This review charts the rapid progress made in elucidating the protein and gene structure, and the mechanism of action of this most recently discovered complement inhibitor, CD59.

Constitutive expression of Ly-6.A2 on murine keratinocytes and inducible expression on TCR gamma delta+ dendritic epidermal T cells

We investigated the expression of Ly-6.A2 on isolated murine epidermal cells by flow cytometry. Ly-6.A2 was expressed on 61% of keratinocytes and 6% of dendritic epidermal T cells of C57BL mice. Phosphatidylinositol-specific phospholipase C removed Ly-6.A2, indicating that the antigen is anchored to the keratinocyte membrane via a glycosyl-phosphatidylinositol anchor similar to its attachment to the membrane of lymphocytes. Induction of dermatitis by topical application of PMA increased the expression of Ly-6.A2 on TCR gamma delta+ dendritic epidermal T cells and did not change its expression on keratinocytes. The increased expression of Ly-6.A2 on dendritic epidermal T cells was transient and reached a peak at 4 days after application of PMA, when 55% of the cells were positive.

Distribution of complement regulators (CD46, CD55 and CD59) in skin appendages, and in benign and malignant skin neoplasms

Immunohistochemical studies were performed to establish the distribution of membrane cofactor protein (MCP; CD46), decay-accelerating (DAF; CD55) and homologous restriction factor (HRF20; CD59), in normal skin appendages, and in benign and malignant skin neoplasms. At least two of these regulators were detected on normal eccrine glands, apocrine glands and sebaceous glands. They were also found in cellular naevi (CN), seborrhoeic keratoses (SK), basal cell carcinoma (BCC), Bowen's disease (BD), squamous cell carcinoma (SCC) and Paget's disease (PD). Although there were slight differences in their distribution, these regulators were found in all the cells examined, indicating that they are essential factors in human skin as well as other organs, and in neoplasms, in preventing autologous complement attack.

Isolation and characterization of the complement-inhibiting protein CD59 antigen from platelet membranes

Several groups have recently described the isolation of a 20 kDa membrane-attack-complex (MAC)-inhibiting protein, termed 'CD59 antigen', from human erythrocyte membranes. Antibodies raised against erythrocyte CD59 antigen detect antigen on the surface of many other cell types, and in some of these cells the antigen has been shown to have a molecular mass similar to that of the erythrocyte protein and to confer resistance to lysis by the MAC. A platelet-membrane form of CD59 antigen has been described and reported to be much larger than the erythrocyte protein. Here I report the isolation of CD59 antigen from platelet membranes and its molecular and functional characterization. The platelet protein is not significantly larger than the erythrocyte form and possesses similar MAC-inhibiting activity. Platelet CD59 antigen is anchored to the membrane via a glycosyl-phosphatidylinositol link, and consequently it is suggested that deficiency of this protein might be responsible for the increased thrombotic tendency observed in paroxysmal nocturnal haemoglobinuria.

Expression and characterization of membrane co-factor protein (MCP) in human skin

Membrane co-factor protein (MCP; CD46) is an integral membrane protein with molecular weight (MW) of the two species of 63 kD and 55 kD, and regulates autologous complement activation, with the activity of factor I cofactor. The quantity of each species is genetically regulated, and two codominantly inherited allelic variants account for the three phenotypic patterns. By immunohistochemical study, MCP was found both in the intercellular spaces of the epidermis and on the endothelial cells in the dermis of normal human skin in vivo. The intensity of the staining pattern was higher in the basal layer than in the granular layer. By Western blot analysis with use of a monoclonal antibody, MCP in the epidermis appeared as several bands ranged from 60-50 kD, with a major band of 56 kD, which was different from those in either polymorphonuclear cells, platelets, and cultured keratinocytes. No other variants were found in the epidermis obtained from skin of 20 normal humans. Complement activation in human skin may be regulated at several steps, including DAF and HRF20, thereby protecting cells from autologous complement attack.

The control of homologous lysis

Complement activation unleashes powerful effector mechanisms against which host cells are protected by homologous restriction factors. These factors are glycolipid-anchored membrane proteins that either induce C3 convertase dissociation (for example decay-accelerating factor) or prevent the full development of the membrane attack complex (for example homologous restriction factor and CD59). In this article Peter Lachmann explores the biology and biochemistry of these important and intriguing molecules.